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The Editorial on the Research Topic
Intellectual Disabilities in Down Syndrome from Birth and Throughout Life: Assessment and
Treatment
Research on the multiple aspects of cognitive impairment in Down syndrome (DS), from genes to
behavior to treatment, has made tremendous progress in the last decade as reflected in current
clinical trials to improve learning and memory. Congenital intellectual disabilities such as DS
originate from the earliest stages of development and both the acquisition of cognitive skills and
neurodegenerative pathologies are cumulative. Comorbidities such as cardiac malformations, sleep
apnea, diabetes, and dementia are frequent in the DS population, as well, and their increased risk in
this genetically sensitized population provides a means of assessing early stages of these pathologies
that affect the entire population.
Persons with DS will develop the histopathology of Alzheimer’s disease (neuritic plaques and
tangles) due to over-expression of genes on chromosome 21, notably the amyloid precursor protein.
Thus, the DS population is at high risk for dementia, something that cannot be predicted in the
population at large. Awareness of the potential role of people with DS in understanding progression
and treatment as well as protective factors for AD is reawakening.
Major pharmaceutical companies have entered the search for ameliorative treatments for
features of DS, and phase II clinical trials to improve learning andmemory are in progress. Enriched
environment, brain stimulation, and alternative therapies are being tested while clinical assessment
is improving, thus increasing the chances of success for therapeutic interventions. Researchers and
clinicians are actively pursuing the possibility of prenatal treatments for many conditions, an area
with a huge potential impact for developmental disorders such as DS but which also faces significant
challenges to assure safety and to assess outcomes. One major barrier to these studies is that there
is no current way to predict the severity of cognitive (or most other) effects in DS, and thus it is not
possible to determine whether an intervention has had a positive effect. This problem is exacerbated
because evaluation of the cognitive state of young babies is at an early stage.
Our goal here is to present an overview of recent advances with an emphasis on behavioral and
cognitive deficits and how these issues change through life in DS. The relevance of comorbidities
to the end phenotypes described and relevance of pharmacological targets and possible treatments
will be considerations throughout. This Topic contains seven original research articles, five reviews,
and one perspective article.
Potier and Reeves Intellectual Disabilities in Down Syndrome
Eight papers are related to clinical work in individuals
with DS.
Liogier d’Arduy et al. from Hoffmann La Roche laboratory,
in their original research article, publish for the first time a
redefined cognitive scale to assess executive function, memory,
and language in DS individuals from 12 to 30 years. They
developed a multicenter observational, non-pharmacological,
and longitudinal study based on a 90 min testing period with
one or two breaks over 6 months with three visits starting at
birth and extending 1–6 months. This study draws the list of
tests that are currently used for the ongoing 26-week Phase
2 study of Basmisanil in young individuals with DS which
was recently extended from 12 to 30 years down to age 6 for
IQ measurement, memory testing using list learning, executive
function, and language assessments that are test–retest reliable
and have no floor effect.
In their review, Edgin et al. propose to consider the end-
state of DS cognitive phenotypes emergent across developmental
time. For language, which is more impaired in children
with DS than expected considering their general mental age,
intervention targeting the very early neural roots of language
will be important. Brain imaging data indicate that network
connectivity is more diffuse in adults with DS with increased
local network synchrony and under-connectivity of long-range
connections leading to language impairments. Sleep disturbances
are present in most children and adults with DS and could
be very detrimental for hippocampal memory consolidation
and word learning, having cascading implications for language
comprehension and everyday social interactions.
Two original research articles are related to language problems
in individuals with DS. De Hoyo et al. study semantic verbal
fluency pattern in young non-demented adults with DS. They
found a clear deficit in retrieval of words (lexicon) beyond
the accession of common words. These values are correlated
with Aβ42 plasma levels. The semantic verbal fluency test may
be useful to predict risk of dementia in individuals with DS.
Channell et al. compare narrative language performances of
children with DS and Fragile X-syndrome (FXS). They used an
episode-based coding scheme to examine macrostructures and
microstructures from stories produced in response to a wordless
picture book. Individuals with DS acquired the conceptual
knowledge for expressing the key story elements but their
narrative macrostructure was impaired, they showed limited
expressive syntactic abilities and had difficulties talking about
others’ perspectives and intentions. These deficits are shared with
FXS. Children with DS take more time to tell a story and use less
verbs than those with FXS.
In their research article, Lee et al. study executive function
profiles in DS. Children with DS have deficits in “cool”
executive functions such as working memory and planning and
fewer deficits in “hit” executive functions involving behavioral
inhibition and emotional control (Lee et al.). These deficits
are relatively stable across development until young adulthood.
Higher-level cognition abilities will have to be evaluated later
in life.
Mc Guire and Defrin review acute and chronic pain
experienced in people with DS, an area where research is limited.
Acute pain appears to be delayed and once perceived it gets
magnified and persists for a longer period of time. Studies remain
to be done on information processing in DS including cognitive
appraisals of the pain, emotional, and behavioral response, and
social context. DS poses an increased risk to experience pain due
to congenital abnormalities and environmental risk factors, and
this can be exacerbated when affected individuals have difficulties
expressing their pain.
Rafii et al. report the feasibility study of the DSBI (Down
Syndrome Biomarker Initiative) on non-demented individuals
with DS. They found greater hippocampal atrophy with amyloid
load and an inverse correlation of amyloid load with regional
glucose metabolism. Interestingly they could identify amyloid
plaques in the retina. This pilot study shows that biomarkers of
AD can be used in DS to assess AD pathology and will be useful
for characterizing larger cohorts and defining readouts for future
clinical trials of disease modifiers.
Finally, Nizetic et al. discuss the dual role of APP in DS and
AD. Familial cases of AD with microduplication of the APP gene
have peculiar pathology with prominent amyloid angiopathy
but do not show intellectual disabilities while individuals with
DS rarely show vascular and mixed dementia but intellectual
disabilities are prevalent. Beyond AD, APP, and Aβ could
potentially affect cognitive dysfunction in DS. The balance
between beneficial and deleterious effects of neuronal activity in
DS is still an open question that will need to be answered in order
to design optimal treatments.
The remaining manuscripts deal with pharmacotherapy and
mouse models for DS and AD in DS.
Souchet et al. present new set of data suggesting the important
role of Dyrk1A in the control of excitation/inhibition imbalance
in DS. They identify changes of expression for a set of proteins
involved in excitation or inhibition and further show that green
tea extracts containing EGCG can restore levels of most of these
markers in adult mice overexpressing Dyrk1a alone or in Ts65Dn
mice. Some of the reported effects of EGCG are likely due to the
presence of caffeine in various extracts, however, decaffeinated
extracts still have a beneficial effect both on behavioral deficits
and on brain markers.
Catuara-Solarz et al. show that a combination of EGCG
and enriched environment in 5–6 month old Ts65Dn mice
rescued hippocampal-dependent learning and memory while
either alone did not. In their study, they developed a new
statistical analysis that identifies a large degree of variance caused
by memory-unrelated effects that could be applied to better
integrate interindividual variations.
Duchon and Hérault review the crucial role of Dyrk1A
in intellectual disability in Autosomal Dominant Mental
Retardation 7 (MRD7). They review potential Dyrk1A inhibitors
such as harmine, flavonoids, catechine, and other natural
products or synthetic compounds which all target the ATP
binding site but also affect other kinases.
Stagni et al. review 34 studies of potential prenatal therapies
that have been tested in Ts65Dn mice, providing preclinical data
that could be applied to perinatal treatment of DS. Fetuses with
DS have brain defects altering neuronal network formation and
functioning. They report only three perinatal treatments (Shh
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agonist, fluoxetine, and EGCG) while five were administered
prenatally (choline, fluoxetine, three treatments against oxidative
stress, and EGCG). The authors suggest that treatment of fetuses
with DS during weeks 12–16 of human pregnancy may have a
significant impact on neurogenesis. Pilot studies are proposed
with fluoxetine, although outcome measures remain unclear (see
below).
Choong et al. review the literature on mouse models of
Alzheimer’s pathology and dementia in DS. They nicely present
data on people with DS and familial AD with either APP
mutations or APP microduplication and discuss the clinical
assessment of dementia in DS individuals who have baseline
cognitive impairments. They further discuss the involvement of
genes from Hsa21 in AD pathology, highlighting the need for
studying mouse models of AD-DS, and extending biomarker
studies that are being undertaken in large cohorts of people with
DS thus contributing to the elucidation of genotype–phenotype
relationships that ultimately lead to dementia.
We have selected contributions for this volume to touch
on the state of progress in a number of immediate areas for
translation. Of course, as one of the most complex genetic
challenges compatible with human survival past term, trisomy 21
remains a formidable challenge for translational studies.
From a basic science standpoint, additional animal models
would be useful for DS and for AD and the relationship between
them. The mouse has proven to be pre-eminent for genetic
studies, but existing behavior paradigms for mice need to be
expanded for aging studies. Further, mice only develop a subset
of the histopathology associated with DS and AD, and then
only when engineered to contain mutations that are strongly
predisposing. Larger models allowing more refined behavior
analysis, better access to anatomical structures and an additional
perspective of how to understand the relevance of animal
pathology to human conditions would be highly valuable. With
the advent of CRISPR-Cas9 technology, it may be possible to
develop models of DS and of DS-AD in the rat and in small
primates (e.g., marmoset).
In the translational interface, the current trials of Basmisanil
(CLEMATIS NCT02024789 in adult and adolescents with
DS and NCT02484703 in children 6–11 years with DS)
and BTD-001 (Balance Therapeutics, ACTRN12612000652875
on the Australian—New Zealand clinical trial registry) are
based substantially on findings in the Ts65Dn mouse model,
established from extensive behavioral, electrophysiological, and
biochemical assessments. A rather large number of different
drugs/supplements/exercise therapies have been demonstrated to
improve performance in learning and memory assays in these
mice (as reviewed by Stagni et al.), and some treatments have
been assessed for impact on neurogenesis or neuroanatomy,
as well. While the findings regarding GABAergic transmission
in Ts65Dn provided a powerful incentive to move treatments
toward the clinic, substantive support for likely mechanisms is
highly desirable. In particular, it would be extremely useful to
explain why treatments with a large variety of molecules selective
for different pharmacological targets can all provide a similarly
beneficial behavioral impact in Ts65Dn. Another consideration
is the pharmaco-chemistry behind treatments, especially those
involving food extracts such as green tea extracts containing
EGCG. Commercially available supplements are complex mixes
of compounds well-documented to vary in composition and
concentration. In many cases, half-lives and toxicity are not
precisely described. Thorough assessment of purified target
compounds, coupled with pharmacokinetics of how they are
metabolized or the synthesis of pure analogs will be an important
next step in moving these compounds to the clinic.
A critical next step for DS and for AD is the development
of biomarkers, especially for early (pre-) stages of disease. The
DS population can be immensely informative in this regard
since all individuals with trisomy 21 develop the histopathology
of AD, while a subset develop dementia by age 60 despite
decades of exposure to elevated amyloid in various forms.
Extension of findings in this area to fluid biomarkers—so-called
“liquid biopsy”—would be tremendously useful. Discovery of
biomarkers that could predict high risk for dementia would
be very useful before applying neuroprotective or anti-amyloid
treatments, such as the ones described recently by Dekker et al.
(2015). These studies may also indicate metabolic or biochemical
differences reflectingmolecules that are protective against disease
progression. Correlating these with increasingly informative
brain imaging approaches may be of use to the entire population,
not just those with DS.
CONCLUSIONS
Clinical applications demand improved testing for and better
understanding of cognitive development and its impairments in
DS throughout life. Learning and memory experts are defining
specific aspects of cognition that are affected in DS and these
tests are being validated at ever earlier ages. These developments
will be critical to a clearer understanding of both ends of life
in DS. At present, the race to perinatal treatment appears to
us to lack critical elements, most notably any possible outcome
measures short of “normality.” We would caution that such an
elusive goal cannot be supported only by a few behavior tests
in a distantly related species. While the ability exists to screen
for some structural anomalies prenatally (e.g., heart defects)
there is currently no method to predict occurrence or severity
of impact on learning and memory, the likelihood of autistic
behaviors, or other cognitive outcomes in a given individual
with DS. At a minimum, development of predictive biomarkers
needs to be studied in longitudinal assessments before fetuses and
babies are exposed to drugs that have the potential to do harm
at critical periods, especially in untested combinations. In the
risk-benefit equation, absence of any quantifiable, reproducible
outcome prediction means there is zero gain, therefore risk is
hardly acceptable. The potential impact of prenatal treatments
for a disorder that arises substantially due to perturbations
in development is obvious and this should make development
of a natural history of DS that includes biomarkers, clinical
endpoints, and repeatable, validated behavior testing a priority
of the highest order for DS research. The appropriate ages and
duration for these treatments remain to be clarified and long term
effects will need to be elucidated.
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In the necessarily narrow sampling of recent activities in
the DS research community presented here, we have tried
to highlight current developments across areas that relate to
cognitive therapy in DS. These discoveries span the entire life,
from pre-natal development to age-related pathologies. It is
rather shocking to note that although trisomy 21 is the most
common genetic cause of intellectual disability whose proximate
cause has been known for more than 50 years and the existence
of which syndrome has been recognized for more than 150 years,
very little is known about the natural history of DS or even of
co-morbidities of penetrance or expressivity among the multiple
possible outcomes.We can andmust do better for these members
of society and recognize that knowledge gained from those with
a genetic predisposition with a number of possible deleterious
outcomes is applicable to all.
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